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Introduction
============

The concept of dual blockade of the renin-angiotensin system originated from an experimental model[@ref1] purporting to show a "synergistic" effect between angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers. The concept seemed so logical and appealing that seemingly beneficial changes in surrogate endpoints such as blood pressure, proteinuria, and endothelial dysfunction became accepted as a free pass for dual blockade having cardioprotective and nephroprotective effects. Despite a lack of solid evidence on the safety and efficacy of dual blockade of the renin-angiotensin system this type of therapy has been mentioned in several sets of guidelines.[@ref2] [@ref3] [@ref4] Thus dual therapy was commonly used in patients with hypertension and with diabetes or proteinuria, or both and also to a lesser extent in those with heart failure resistant to treatment. Even patients with uncomplicated essential hypertension were not entirely able to escape this fashionable trend. In the United States more than 200 000 patients are currently treated with dual blockade of the renin-angiotensin system, most of them by the combination of an angiotensin receptor blocker and ACE inhibitor (70%).[@ref5] [@ref6] Some other combinations are also used, such as two ACE inhibitors (15%), two angiotensin receptor blockers (5%), and ACE inhibitors or angiotensin receptor blockers in combination with a direct renin inhibitor (8%).[@ref5] The long term efficacy and safety of dual blockade is not, however, well defined.

We compared the long term efficacy of dual blockade of the renin-angiotensin system (any two of ACE inhibitors, angiotensin receptor blockers, or aliskiren) with monotherapy and evaluated adverse events in patients receiving dual therapy compared with monotherapy.

Methods
=======

We systematically searched PubMed, Embase, and the Cochrane central register of controlled trials (Cochrane Library Issue 6, June 2012) using the key terms "ACE inhibitors", "angiotensin receptor blockers", "direct renin inhibitors" and using the names of individual drugs (see supplementary table 1). The search was restricted to randomised controlled trials in humans and in peer reviewed journals from 1990 to August 2012. No language restriction was applied. We checked the reference lists of the reviewed articles and original studies identified by the electronic search for other potentially eligible articles.

Study selection and data extraction
-----------------------------------

Two authors (KD and AS) searched the data independently and in duplicate. Disagreements were resolved by consensus. For this analysis we extracted the year of publication, baseline characteristics of the study population, sample size, type of drug, mean age, study duration, percentage of men, long term efficacy (all cause mortality, cardiovascular mortality, and admissions to hospital for heart failure), and safety events (hyperkalaemia, hypotension, renal failure, and withdrawal owing to drug related adverse events). Hyperkalaemia was defined in the included studies as a serum concentration of potassium greater than 5.5 mmol/L and renal failure as a serum creatinine concentration greater than 176.8 μmol/L (\>2.0 mg/dL) or a doubling of baseline serum creatinine level. The definition of hypotension in the studies varied from symptomatic hypotension to evidence of low blood pressure. Withdrawal owing to drug related adverse events was defined as withdrawal by a patient as a result of any of the clinical or biochemical adverse events.

Selection criteria
------------------

We screened the trials for eligibility using the following criteria: randomised clinical trials comparing individual blockers with a combination of blockers (ACE inhibitor, angiotensin receptor blocker, or direct renin inhibitor), data on either long term efficacy (duration ≥1 year) or safety events (duration ≥4 weeks), and a sample size of at least 50. Given the limited number of trials reporting data on stroke and myocardial infarction, these outcomes were not evaluated in the study.

Quality assessment
------------------

The criteria used for quality assessment were sequence generation of allocation; allocation concealment; masking of participants, staff, and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias, as recommended by the Cochrane Collaboration.[@ref7] We classed studies with high or unclear risk of bias for any of the first three components to be of low quality.

Statistical analysis
--------------------

The statistical analysis was done in line with recommendations from the Cochrane Collaboration and the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines[@ref8] using Review Manager (RevMan), version 5.1.7 (Cochrane Collaboration, 2012). Heterogeneity was assessed using the I^2^ statistic. I^2^ is the proportion of total variation observed between the trials attributable to differences between trials rather than to sampling error (chance), and we considered I^2^ \<25% as representing low heterogeneity and I^2^ \>75% as representing high heterogeneity. We used the random effects model of DerSimonian and Laird[@ref9] to calculate the effect sizes because of known clinical and methodological heterogeneity of the studies. All analyses were performed using the intention to treat principle. Results were calculated by relative risk ratio and 95% confidence intervals using the Mantel-Haenszel method. We carried out head to head comparisons between individual blockers and the combination of blockers for both long term efficacy and safety data. Analysis was stratified by patient cohorts with and without heart failure. Analysis was also done to evaluate the safety outcomes between dual blockers (ACE inhibitors+angiotensin receptor blockers, angiotensin receptor blockers+aliskiren, ACE inhibitors+aliskiren) and individual blockers.

Publication bias was estimated visually by funnel plots[@ref10] or by Begg's test and the weighted regression test of Egger.[@ref11] If there was evidence of publication bias, we applied the trim and fill method to adjust the results of the meta-analysis.[@ref12]

Sensitivity analysis
--------------------

Sensitivity analysis was performed for safety outcomes based on the cohort of patients with heart failure versus the cohort without, risk of bias in the trial (low *v* high), duration of follow-up (\<1 year *v* ≥1year), and number of patients (\<500 *v* ≥500). We used a test for interaction to estimate differences between the subgroups.[@ref13] Sensitivity analysis was not done for long term efficacy outcomes because of the limited number of studies available.

Results
=======

A total of 138 full text articles were assessed for eligibility, of which 33 met the inclusion criteria (fig 1[](#fig1){ref-type="fig"}). The 33 trials[@ref14] [@ref15] [@ref16] [@ref17] [@ref18] [@ref19] [@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] enrolled 68 405 patients with a mean age of 61 (SD 4) years, 71% men, followed-up for a mean duration of 52 weeks (table 1[](#tbl1){ref-type="table"}). A combination of an ACE inhibitor and angiotensin receptor blocker was used in 22 trials,[@ref14] [@ref15] [@ref16] [@ref17] [@ref18] [@ref19] [@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] an ACE inhibitor and aliskiren in three trials,[@ref36] [@ref37] [@ref38] an angiotensin receptor blocker and aliskiren in seven trials,[@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] and an ACE inhibitor or angiotensin receptor blocker with aliskiren in one trial.[@ref46]

![**Fig 1** Selection of studies. ACE=angiotensin converting enzyme inhibitor](makh008194.f1_default){#fig1}

###### 

Characteristics of included studies

  Trial name, year                                                          Patient cohort                                                              No of patients   Mean age (years)   Men (%)   Follow-up (weeks)   RAS blocker monotherapy     RAS blocker combination          Risk of bias   Data available
  ------------------------------------------------------------------------- --------------------------------------------------------------------------- ---------------- ------------------ --------- ------------------- --------------------------- -------------------------------- -------------- ---------------------
  ACE inhibitor/ARB combination *v* RAS blocker monotherapy:                                                                                                                                                                                                                                          
   AMAZE^14^2004                                                            Essential hypertension                                                      1096             54                 58        8                   Lisinopril                  Lisinopril+candesartan           High           Safety
   Azizi et al^15^ 2000                                                     Mild to moderate hypertension                                               177              NR                 64        6                   Enalapril or losartan       Enalapril+losartan               High           Safety
   CALM^16^2001                                                             Diabetes, hypertension and microalbuminuria                                 197              60                 65        24                  Lisinopril or candesartan   Lisinopril+candesartan           High           Safety
   CALM II^17^2005                                                          Hypertension and diabetes                                                   75               55                 75        52                  Lisinopril                  Lisinopril+candesartan           High           Safety
   CHARM Added^18^2003                                                      Heart failure and ejection fraction ≤40%                                    2548             64                 79        178                 Any ACE inhibitor           ACE inhibitor+candesartan        Low            Efficacy and safety
   Cice et al^19^2010                                                       Haemodialysis, heart failure with ejection fraction ≤40%                    332              63                 54        156                 Any ACE inhibitor           ACE inhibitor+telmisartan        Low            Efficacy and safety
   IMPROVE^20^ 2007                                                         High risk cardiovascular disease and microalbuminuria                       405              66                 61        20                  Ramipril                    Ramipril+irbesartan              High           Safety
   Kanno et al^21^2006                                                      Hypertension and chronic kidney disease                                     90               60                 40        156                 Any ACE inhibitor           ACE inhibitor+candesartan        Low            Safety
   Kum et al^22^ 2008                                                       Chronic systolic heart failure with ejection fraction \<50%                 50               66                 72        52                  Any ACE inhibitor           ACE inhibitor+irbesartan         High           Efficacy and safety
   Mehdi et al^23^2009                                                      Diabetes, hypertension, and albuminuria                                     81               50                 48        48                  Lisinopril                  Lisinopril+losartan              High           Safety
   Ogawa et al^24^ 2007                                                     Hypertension and diabetic nephropathy                                       164              62                 48        96                  Temocapril, candesartan     Temocapril+candesartan           High           Safety
   ONTARGET^25^2008                                                         High risk cardiovascular disease                                            25 620           67                 73        243                 Ramipril or telmisartan     Ramipril+telmisartan             Low            Efficacy and safety
   RESOLVD^26^1999                                                          Heart failure with ejection fraction \<40%                                  768              64                 83        43                  Enalapril or candesartan    Enalapril+candesartan            Low            Safety
   Ruilope et al^27^2000                                                    Hypertension, chronic kidney disease with or without proteinuria            108              57                 70        4                   Valsartan                   Benazepril+valsartan             High           Safety
   Titan et al^28^2011                                                      Diabetic nephropathy                                                        56               58                 63        16                  Enalapril                   Enalapril+losartan               High           Safety
   Tonkon et al^29^2000                                                     Chronic heart failure                                                       109              64                 76        12                  Any ACE inhibitor           ACE inhibitor+irbesartan         High           Safety
   VALERIA^30^2008                                                          Hypertension and microalbuminuria                                           133              59                 69        30                  Lisinopril or valsartan     Lisinopril+valsartan             Low            Safety
   Val-HeFT^31^2001                                                         NYHA class II-IV heart failure                                              5010             63                 80        100                 Any ACE inhibitor           ACE inhibitor+valsartan          Low            Efficacy and safety
   V-HeFT^32^1999                                                           Symptomatic NYHA class II-IV heart failure                                  83               64                 100       4                   Any ACE inhibitor           ACE inhibitor+valsartan          High           Safety
   VALIANT^33^2003                                                          Acute myocardial infarction complicated by heart failure                    14 703           65                 69        107                 Captopril or valsartan      Captopril+valsartan              Low            Efficacy and safety
   White et al^34^2007                                                      Symptomatic heart failure with ejection fraction ≤40%                       80               62                 90        26                  Any ACE inhibitor           ACE inhibitor+candesartan        High           Safety
   Yasamura et al^35^ 2004                                                  Mild to moderate chronic heart failure                                      106              65                 80        26                  Any ACE inhibitor           ACE inhibitor+ARB                High           Safety
  ACE inhibitor/aliskiren combination *v* RAS blocker monotherapy:                                                                                                                                                                                                                                    
   ALOFT^36^2008                                                            Hypertension and NYHA class II-IV heart failure                             302              67                 78        12                  Any ACE inhibitor           ACE inhibitor+aliskiren          Low            Safety
   ASPIRE^37^2011                                                           Post-myocardial infarction with systolic dysfunction                        820              60                 82        36                  Any ACE inhibitor           ACE inhibitor+aliskiren          Low            Safety
   Uresin et al^38^2007                                                     Diabetes mellitus and hypertension                                          837              59                 59        8                   Ramipril or aliskiren       Ramipril+aliskiren               Low            Safety
  ARB/aliskiren combination *v* RAS blocker monotherapy:                                                                                                                                                                                                                                              
   ALLAY^39^2009                                                            Hypertension and left ventricular hypertrophy                               460              59                 76        36                  Losartan or aliskiren       Losartan+aliskiren               Low            Safety
   AVANTE GARDE^40^2010                                                     Acute coronary syndrome without heart failure, raised natriuretic peptide   1101             63                 68        8                   Valsartan or aliskiren      Valsartan+aliskiren              Low            Safety
   AVOID^41^2008                                                            Hypertension and diabetic nephropathy                                       599              62                 71        24                  Losartan                    Losartan+aliskiren               Low            Safety
   Drummond et al^42^ 2011                                                  Diabetes mellitus and hypertension                                          363              57                 54        12                  Valsartan                   Valsartan+aliskiren              Low            Safety
   Oparil et al^43^2007                                                     Hypertension                                                                1797             52                 61        8                   Valsartan or aliskiren,     Valsartan+aliskiren              Low            Safety
   Pool et al^44^2007                                                       Mild to moderate hypertension                                               1123             56                 56        8                   Valsartan or aliskiren      Valsartan+aliskiren              Low            Safety
   VANTAGE^45^2010                                                          Stage 2 hypertension                                                        451              57                 51        8                   Valsartan                   Valsartan+aliskiren              High           Safety
  ACE inhibitor or ARB/aliskiren combination *v* RAS blocker monotherapy:                                                                                                                                                                                                                             
   ALTITUDE^46^ 2012                                                        Diabetic nephropathy                                                        8561             65                 68        139                 Aliskiren                   ACE inhibitor or ARB+aliskiren   Low            Efficacy and safety

ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker; RAS=renin-angiotensin system; NR=not recorded; NYHA=New York Heart Association.

Efficacy data were available from seven trials with a total of 56 824 patients (mean age 65 (SD 2) years, 72% males) and mean duration of 2.7 years. Safety data were available from all of the included trials.

Of the 33 trials, 18 reported adequate generation of allocation sequence and adequate allocation concealment and 24 reported adequate masking of participants, staff, and outcome assessors. On the basis of quality assessment, 18 were deemed to be at low risk of bias and the remainder to be at high risk.

Dual therapy versus monotherapy: efficacy outcomes
--------------------------------------------------

### All cause mortality

Data were available from seven trials with a total of 56 824 patients. Overall, 3314 of 21 638 patients (15.3%) died in the dual therapy group compared with 5286 of 35 186 patients (15.0%) in the monotherapy group. When compared with monotherapy alone, dual therapy had no benefit on all cause mortality (relative risk 0.97, 95% confidence interval 0.89 to 1.06, P=0.50, I^2^=69%, fig 2[](#fig2){ref-type="fig"}).

![**Fig 2** Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for all cause mortality. Error bars represent 95% confidence intervals and data marker sizes indicate sample sizes of cohorts. ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor, M-H=Mantel-Haenszel](makh008194.f2_default){#fig2}

In subgroup analysis, dual therapy showed no benefit for all cause mortality in the cohort with heart failure (0.92, 0.82 to 1.03, P=0.15), however mortality was increased in the cohort without heart failure (1.07, 1.00 to 1.14, P=0.04, fig 2). The difference between these two subgroups was significant (P=0.02).

### Cardiovascular mortality

In six trials 2812 of 19 127 patients (14.7%) died of cardiovascular causes in the dual therapy group compared with 5128 of 32 687 patients (15.7%) in the monotherapy group. Dual therapy had no significant benefit on cardiovascular mortality (0.96, 0.88 to 1.05, P=0.38, I^2^=59%, fig 3[](#fig3){ref-type="fig"}) compared with monotherapy.

In subgroup analysis, dual therapy had no benefit on cardiovascular mortality in the cohorts both with heart failure (P=0.14) and without (P=0.61).

![**Fig 3** Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for cardiovascular mortality. ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor, M-H=Mantel-Haenszel](makh008194.f3_default){#fig3}

### Admissions to hospital for heart failure

In five trials 1825 of 16 728 patients (10.9%0 in the dual therapy group were admitted to hospital for heart failure compared with 2604 of 25 343 patients (10.3%) in the monotherapy group. Dual therapy was associated with a 18% reduction in admissions to hospital for heart failure compared with monotherapy (0.82, 0.74 to 0.92, I^2^=68%, P=0.0003, fig 4[](#fig4){ref-type="fig"}). This was largely driven by a benefit in the cohort with heart failure (0.77, 0.68 to 0.88, P=0.0001), although there was a trend towards benefit in the cohort without heart failure (0.91, 0.82 to 1.01, P=0.07).

![**Fig 4** Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for admissions to hospital for heart failure. ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor, M-H=Mantel-Haenszel](makh008194.f4_default){#fig4}

Dual therapy versus monotherapy: safety outcomes
------------------------------------------------

### Hyperkalaemia

In 23 trials 2188 of 22 717 patients (9.6%) had hyperkalaemia in the dual therapy group compared with 1887 of 37 921 patients (4.9%) in the monotherapy group. Dual therapy was associated with a 55% increased risk of hyperkalaemia (1.55, 1.32 to 1.82, I^2^=50%, P\<0.001, fig 5[](#fig5){ref-type="fig"}) compared with monotherapy.

In subgroup analysis, the risk of hyperkalaemia increased significantly in both the cohort with heart failure (P=0.02) and the cohort without (P\<0.001).

![**Fig 5** Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for hyperkalaemia. ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; M-H=Mantel-Haenszel](makh008194.f5_default){#fig5}

### Hypotension

In 18 trials 2042 of 23 572 patients (8.7%) had hypotension in the dual therapy group compared with 2227 of 37 680 patients (5.9%) in the monotherapy group. Dual therapy was associated with a 66% increased risk of hypotension (1.66 1.38 to 1.98, I^2^=66%, P\<0.001, fig 6[](#fig6){ref-type="fig"}) compared with monotherapy.

In subgroup analysis, the risk of hypotension increased significantly in the cohorts both with heart failure (P\<0.001) and without (P=0.002).

![**Fig 6** Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for hypotension, ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor, M-H=Mantel-Haenszel](makh008194.f6_default){#fig6}

### Renal failure

In 20 trials 2026 of 24 536 patients (8.3%) had renal failure in the dual therapy group compared with 2551 of 39 784 patients (6.4%) in the monotherapy group. Dual therapy was associated with a 41% increased risk of renal failure (1.41, 1.09 to 1.84, I^2^=83%, P=0.01, fig 7[](#fig7){ref-type="fig"}) compared with monotherapy.

In subgroup analysis, the risk of renal failure increased significantly in the cohort with heart failure (2.19, 1.82 to 2.65, P\<0.001) but not in the cohort without (1.04, 0.80 to 1.35, P=0.76). The difference between these two subgroups was significant (P\<0.001).

![**Fig 7** Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for renal failure. ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor, M-H=Mantel-Haenszel](makh008194.f7_default){#fig7}

### Withdrawal owing to drug related adverse events

In 26 trials 4265 of 24 994 patients (17.1%) had withdrawal owing to drug related adverse events in the dual therapy group compared with 5825 of 40 247 patients (14.5%) in the monotherapy group. Dual therapy was associated with a 27% increase in the risk of withdrawal owing to drug related adverse events (1.27, 1.21 to 1.32, I^2^=2%, P\<0.001, fig 8[](#fig8){ref-type="fig"}) compared with monotherapy.

![**Fig 8** Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for withdrawal owing to drug related to adverse events](makh008194.f8_default){#fig8}

In subgroup analysis, the risk of withdrawal owing to drug related adverse events increased significantly in the cohort both with heart failure (P\<0.001) and without (P=0.0003).

Subgroup analysis of safety outcomes
------------------------------------

Comparing the combination of ACE inhibitors and angiotensin receptor blockers with ACE inhibitors alone, the risk of all safety outcomes (hyperkalaemia, hypotension, renal failure, and withdrawal owing to drug related adverse events) increased significantly with combination treatment: (table 2[](#tbl2){ref-type="table"}). Comparing the combination of ACE inhibitors and angiotensin receptor blockers with angiotensin receptor blockers alone, the risk of hypotension and withdrawal owing to drug related adverse events increased significantly but not the risk of hyperkalaemia and renal failure with combination treatment (table 2). Comparing the combination of ACE inhibitors and aliskiren with ACE inhibitors alone, the risk of hyperkalaemia and hypotension increased significantly but there was no difference in the risk of renal failure and withdrawal owing to drug related adverse events with combination treatment (table 2). Comparing the combination of ACE inhibitors and aliskiren with aliskiren alone, the risk of hyperkalaemia, hypotension, renal failure, and withdrawal owing to drug related adverse effects did not differ with combination treatment (table 2). Comparing the combination of angiotensin receptor blockers and aliskiren with angiotensin receptor blockers alone, the risk of hyperkalaemia was increased significantly but there was no difference in the risk of other adverse events (table 2). Comparing the combination of angiotensin receptor blockers and aliskiren with aliskiren alone, none of the adverse events differed significantly between the two groups (table 2). These subgroup analyses are presented as forest plots in supplementary figures 1-4.

###### 

 Safety outcomes between different drug combinations for dual blockade of the renin-angiotensin system (RAS) compared with monotherapy

  RAS blocker combination *v.* monotherapy           Relative risk (95% CI), P value   Interaction P value             
  -------------------------------------------------- --------------------------------- ------------------------------- ------
  ACE inhibitors+angiotensin receptor blockers:      ACE inhibitors                    Angiotensin receptor blockers   
   Hyperkalaemia                                     1.83 (1.35 to 2.50), 0.0001       1.34 (0.86 to 2.09), 0.19       0.26
   Hypotension                                       2.02 (1.46 to 2.80), \<0.001      1.44 (1.04 to 2.01), 0.03       0.15
   Renal failure                                     1.55 (1.23 to 1.96), 0.0002       1.15 (0.92 to 1.43), 0.22       0.07
   Withdrawal owing to drug related adverse events   1.21 (1.16 to 1.26), \<0.001      1.39 (1.14 to 1.70), 0.001      0.18
  ACE inhibitors+aliskiren:                          ACE inhibitors                    Aliskiren                       
   Hyperkalaemia                                     1.70 (1.11 to 2.58), 0.01         2.55 (1.00 to 6.46), 0.05       0.44
   Hypotension                                       1.97 (1.17 to 3.30), 0.02         No studies available            NA
   Renal failure                                     1.75 (0.92 to 3.34), 0.09         0.34 (0.04 to 3.24), 0.35       0.16
   Withdrawal owing to drug related adverse events   0.97 (0.34 to 2.74), 0.95         0.56 (0.21 to 1.48), 0.24       0.45
  Angiotensin receptor blockers+aliskiren:           Angiotensin receptor blockers     Aliskiren                       
   Hyperkalaemia                                     1.40 (1.02 to 1.91), 0.04         1.49 (0.83 to 2.68), 0.18       0.86
   Hypotension                                       1.62 (0.70 to 3.74), 0.26         1.02 (0.66 to 1.56), 0.94       0.34
   Renal failure                                     1.13 (0.52 to 2.47), 0.76         1.02 (0.36 to 2.93), 0.97       0.88
   Withdrawal owing to drug related adverse events   1.06 (0.79 to 1.43), 0.70         1.19 (0.54 to 2.66), 0.67       0.79

ACE=angiotensin converting enzyme; NA=not applicable.

Sensitivity analyses did not show any significant difference in the groups for hyperkalaemia, hypotension, or withdrawal owing to drug related adverse effects. The risk of renal failure was significantly higher in the cohort of patients with heart failure compared with the cohort without heart failure (P\<0.001, see supplementary table 2).

Significant heterogeneity was present in most of the analyses. Thus a random variance model was used. No evidence of publication bias was suggested by visual inspection of funnel plots or by Egger's test. The results were not significantly different after applying the trim and fill method all cause mortality (relative risk 0.94, 95% confidence interval 0.86 to 1.03), cardiovascular mortality (0.96, 0.86 to 1.04), admissions to hospital for heart failure (0.82, 0.74 to 0.91), hyperkalaemia (1.44, 1.22 to 1.70), hypotension (1.59, 1.33 to 1.91), renal failure (1.47, 1.13 to 1.92), and withdrawal owing to drug related adverse events (1.27, 1.20 to 1.34) (see supplementary figure 5).

Discussion
==========

The present analysis evaluating the long term efficacy and safety of dual blockade of the renin-angiotensin system failed to show any benefit for all cause mortality and cardiovascular mortality with dual therapy compared with monotherapy. This is the most comprehensive review of literature evaluating both the safety and outcomes of dual therapy. Although compared with monotherapy dual therapy was associated with a reduction in admissions to hospital for heart failure mainly in the cohort with heart failure, the risks of hyperkalaemia, hypotension, renal failure, and withdrawal owing to drug related adverse events were significantly increased. Given these facts it may appropriately be asked why dual therapy was and still is extensively used to treat many patients with hypertension and heart failure. With the exception of the CHARM Added trial,[@ref18] most if not all data making dual therapy attractive are based on evidence from surrogate endpoints.

One meta-analysis[@ref47] reported "encouraging" evidence that dual therapy reduced proteinuria by an incremental 20-25% compared with monotherapy. The COOPERATE study[@ref48] even showed that dual therapy with trandolapril and losartan reduced the risk of the primary endpoint (time to doubling of serum creatinine level or end stage renal disease) by 60% better than monotherapy, thereby becoming one of the most widely quoted studies by the *Lancet*.[@ref49] After such seemingly robust evidence many physicians accepted that reduction of albuminuria or proteinuria was synonymous with nephroprotection. In the CHARM Added trial,[@ref18] in a cohort of 2548 patients with heart failure, dual blockade of the renin-angiotensin system (candesartan and ACE inhibitor) significantly reduced the primary outcome of cardiovascular death or admission to hospital for worsening of heart failure. As a consequence, dual therapy became more and more used in patients with hypertension, diabetes, and heart failure resistant to treatment.

The importance of dual therapy began to change with publication of the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).[@ref50] Similar to other studies, in this study the surrogate endpoint albuminuria was reduced with dual therapy compared with monotherapy. However, a significant doubling of creatinine level and dialysis in the combination arm (despite less albuminuria) argued against a nephroprotection by dual therapy. More recently, authors[@ref51] found several inconsistencies in COOPERATE, eventually leading to retraction of the study by the *Lancet*.[@ref52]

In heart failure, the safety issue remained a major concern with dual therapy. In the CHARM Added trial, hyperkalaemia was almost five times more common and increased creatinine levels twice as common with dual therapy than with monotherapy. A meta-analysis[@ref53] in over 18 000 patients with left ventricular dysfunction showed a significantly increased risk of adverse events of dual therapy compared with monotherapy, leading to the discontinuation of dual therapy. Given the adverse effects and lack of consistent survival benefits, the addition of an angiotensin receptor blocker to ACE inhibitor therapy in patients with heart failure should perhaps be reserved only for selected patients who continue to have symptoms while receiving monotherapy and cannot tolerate mineralocorticoid antagonists.

Several trials have shown a beneficial effect of aliskiren in combination with ACE inhibitors or angiotensin receptor blockers in patients with heart failure or diabetic nephropathy on surrogate endpoints, such as in proteinuria,[@ref41] left ventricular hypertrophy,[@ref39] and neurohormonal changes.[@ref36] Our analysis showed a significantly increased risk of hyperkalaemia with combination therapy with aliskiren compared with monotherapy. Similar results were also found in a recent meta-analysis of 10 studies with over 4800 patients.[@ref54] The ALTITUDE trial[@ref46] was terminated early because of an increased risk of adverse outcomes (stroke, hypotension, and hyperkalaemia) when aliskiren was combined with ACE inhibitors or angiotensin receptor blockers. As to the mechanism of hypotension, one author suggested that blockade of the renin-angiotensin-aldosterone system could trigger the Bezold-Jarisch reflex sensitised by withdrawal of the effect of angiotensin II.[@ref55] More extensive blockade of the renin-angiotensin system with two drugs could lead to a reduction in sympathetic outflow from the brainstem and excessive vagal tone causing prolonged hypotension and bradycardia. Conceivably this mechanism might account for the higher incidence of stroke and hypotension in patients receiving dual therapy.[@ref55] Regulatory agencies such as the Food and Drug Administration and European Medicines Agency[@ref56] recommended avoiding aliskiren in patients with diabetes or moderate to severe renal dysfunction who are already taking ACE inhibitors or angiotensin receptor blockers. Of note, the VA NEPHRON-D multicentre trial[@ref57] to assess the effect of combination of losartan and lisinopril compared with losartan alone, on the progression of kidney disease in 1850 patients with diabetes and overt proteinuria was terminated recently for similar reasons to those of ALTITUDE.

The present data evolving from studies with dual blockade of the renin-angiotensin system should be a reminder hat many purported benefits of such therapy was solely based on data using surrogate endpoints. Surrogate endpoints not uncommonly fail to emulate hard outcomes endpoints and leapfrogging from surrogate data cannot substitute for the exposure of patients in clinical outcome studies.

Strengths and limitations of this meta-analysis
-----------------------------------------------

Our paper had several limitations. As with other meta-analyses, given the lack of data in each trial, we did not adjust our analysis for adherence to therapy. Also, the results are subject to limitations inherent to any meta-analysis based on pooling of data from different trials with different duration, doses of drugs, definitions for safety outcomes, and patient groups. Analysis of safety events is also prone to several biases since the data vary in each study for quality, incidence, severity, and adjudication. The reporting may also be influenced by expectations of the investigators, sponsors, and patients. Despite all the limitations, this is the most comprehensive analysis evaluating the safety and efficacy of dual blockade of the renin-angiotensin system. Despite significant heterogeneity among the studies, there was no evidence of publication bias visually and by Egger's test. The results were fairly consistent among various subgroups.

Conclusion
----------

Although dual blockade of the renin-angiotensin system may have seemingly beneficial effects on certain surrogate endpoints, it failed to reduce mortality and was associated with an excessive risk of adverse events such as hyperkalaemia, hypotension, and renal failure when compared with monotherapy. The overall risk to benefit ratio argues against the use of dual therapy.

### What is already known on this topic

1.  Dual blockade of the renin-angiotensin system (RAS) is extensively used for treatment of resistant forms of heart failure, hypertension, diabetic nephropathy, and proteinuria

2.  The efficacy and safety of dual RAS blockade, however, remains controversial

### What this study adds

1.  Although dual RAS blockade reduced admissions to hospital for heart failure (mainly in patients with heart failure), it had no effect on all cause or cardiovascular mortality

2.  Compared with monotherapy, dual therapy was associated with a significant increase in adverse events such as hyperkalaemia, hypotension, and renal failure

3.  These considerations of risk-benefit argue against the routine use of dual therapy
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